In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e16695-e16695
Abstract:
e16695 Background: 90% of pancreatic cancers are adenocarcinomas. Pancreatic neuroendocrine tumors (PNET) are much less common. However, some adenocarcinomas carry a neuroendocrine component and have an effect on the hormonal profile of the body. The purpose of the study was to analyze the content of steroid hormones and ACTH in the blood of patients with pancreatic cancer in dependence on the neuroendocrine component presence. Methods: Standard RIA methods were used to measure blood level of testosterone (T), estradiol (E2), progesterone (P4), cortisol and ACTH in 10 patients with pancreatic adenocarcinoma (PA), 12 patients with PNET and 20 patients with PA with a neuroendocrine component (PA+NEC). The results were compared with the levels in 23 healthy donors. All patients gave voluntary informed consent for the study. Results: Levels of all measured hormones were elevated in the blood of patients with PA: T by 1.8 times, P4 by 4.8 times, E2 by 2.7 times, cortisol by 2 times and ACTH by 2.5 times, compared to donors. In PNET, E2 was 1.5 times (p 〈 0.05) lower, and T 1.6 times (p 〈 0.05) higher than in donors. Levels of P4, ACTH and cortisol in PNET were similar to normal values. In PA+NEC, T was decreased by 1.3 times, P4 and ACTH increased by 1.4 and 2.2 times respectively. E2 and cortisol were similar to normal values. Conclusions: The hormonal profiles of patients with PNET and PA differ, except T with blood levels increasing in both tumors. The presence of NEC in PA decreases blood levels of T and normalizes E2 and cortisol.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2020.38.15_suppl.e16695
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2020
detail.hit.zdb_id:
2005181-5
Bookmarklink